Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Payables (2018 - 2025)

X4 Pharmaceuticals' Payables history spans 8 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Payables fell 33.93% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, down 33.93%, while the annual FY2025 figure was $5.7 million, 33.93% down from the prior year.
  • Payables reached $5.7 million in Q4 2025 per XFOR's latest filing, up from $5.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $11.1 million in Q1 2025 to a low of $2.4 million in Q3 2021.
  • Average Payables over 5 years is $6.2 million, with a median of $5.8 million recorded in 2023.
  • Peak YoY movement for Payables: surged 147.68% in 2021, then tumbled 41.09% in 2025.
  • A 5-year view of Payables shows it stood at $4.3 million in 2021, then surged by 81.58% to $7.8 million in 2022, then grew by 15.04% to $8.9 million in 2023, then dropped by 3.64% to $8.6 million in 2024, then tumbled by 33.93% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Payables are $5.7 million (Q4 2025), $5.1 million (Q3 2025), and $7.7 million (Q2 2025).